Franklin Biolabs Partners with RareMoon Consulting to Enhance Preclinical Development with Regulatory Expertise

Franklin Biolabs and RareMoon Consulting: A New Partnership

In an exciting development in the realm of genetic medicine, Franklin Biolabs, a leading preclinical contract research organization (CRO), has announced a strategic partnership with RareMoon Consulting, a firm specializing in regulatory services for orphan drugs and advanced therapies. This collaboration is set to revolutionize the pathway from preclinical development to clinical trials, particularly for treatments targeting rare diseases.

The partnership aims to merge scientific expertise with regulatory knowledge, thereby creating a streamlined process for companies aiming to transition from nonclinical stages to clinical submissions. According to Dr. Vatsala Naageshwaran, CEO of Franklin Biolabs, this alliance enhances their capabilities to support pharmaceutical and biotech clients in preparing Investigational New Drug (IND) and Biologics License Application (BLA) submissions.

By working closely with RareMoon, Franklin Biolabs aims to construct nonclinical programs that are meticulously aligned with regulatory expectations, ensuring that projects avoid unnecessary studies that do not contribute to the progression of the therapy. This not only reduces development risks but also expedites timelines for reaching the clinic, which is crucial for patients in dire need of innovative therapies.

Sabrina Mogle, CEO of RareMoon Consulting, highlighted the potential of this partnership to transform how sponsors approach development programs. “By prioritizing regulatory requirements and focusing on critical data, we can support better planning and execution. This strategic alignment reinforces our commitment to efficient and regulatory-ready programs,” Mogle stated.

The partnership's integration of structured development plans is particularly vital in the current landscape, where the urgency for effective therapies for rare diseases is more pronounced than ever. Companies will benefit from reduced delays and streamlined processes, allowing for faster delivery of much-needed medicines to market.

Both Franklin Biolabs and RareMoon Consulting will showcase their partnership at the upcoming ASGCT Annual Meeting scheduled for May 12-14 in Boston. Attendees will have the opportunity to learn more about the expanded capabilities this collaboration brings to developers of gene therapies and rare disease treatments.

About Franklin Biolabs

Franklin Biolabs is a premier CRO focused on accelerating the development of gene therapies and biologics. Headquartered in Philadelphia and founded by renowned gene therapy pioneer Dr. Jim Wilson, the organization offers a full suite of services, including crafting viral vectors, analytics, and conducting preclinical studies.

About RareMoon Consulting

RareMoon Consulting provides regulatory affairs guidance aimed at companies developing treatments for rare diseases. Their expertise spans various therapeutic areas, including biologics and small molecules. By assisting clients from early development stages through IND preparation, RareMoon helps clients navigate the complex regulatory landscape effectively.

This strategic partnership between Franklin Biolabs and RareMoon Consulting marks a significant advancement in the landscape of gene therapy development. By blending scientific rigor with essential regulatory insight, the collaboration promises to deliver more efficient paths for therapeutic development, ultimately benefiting patients who rely on innovative medical solutions.